Skip to main content
. 2021 Jul;9(14):1148. doi: 10.21037/atm-21-2589

Figure 3.

Figure 3

The frequency of PMN-MDSCs in the peripheral blood obtained from cancer patients and healthy donors. (A) CD15+CD14− PMN-MDSCs were also significantly increased compared with those in normal donors (mean 13.19% vs. 1.93%, P<0.0001). (B) Compared to normal donors, the number of PMN-MDSCs in cancer patients was (mean 1.88% vs. 7.55%, 10.28%, and 15.47% for healthy vs. stage I, II, and III; P<0.0001, P<0.0001, P<0.0001, respectively). A direct correlation between clinical cancer stage and PMN-MDSCs percentage was observed for stage I vs. II (P=0.0364), stage I vs. III (P<0.0001) and stage II vs. III (P=0.0167), respectively. No correlation was observed between the PMN-MDSCs and a TNM stage (C) or tumor differentiation (D) stage. * indicates a P value of <0.05; *** indicates a P value of <0.0001. PMN-MDSCs, polymorphonuclear myeloid-derived suppressor cells; TNM, tumor, node, metastasis; Health, healthy volunteers; Patients, HNSCC patients.